Rida is pretty much in the bag. Pona is looking better everyday. And with the great results shown by Crizotinib, 113 should start generating some further interest.
What do you think of the drugs in INCY's pipeline?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.